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MSA increases the stability of GKLF mRNA. We next performed an mRNA stability assay under the condition in which new RNA synthesis was blocked. Actinomycin D, an RNA synthesis inhibitor, was added to the culture at the time of MSA treatment, and GKLF mRNA levels were followed in a 6-hr time course by real-time RT-PCR analysis. Since actinomycin D could be cytotoxic, we also monitored cell growth for a duration of up to 8 hr and did not observe cell death or significant growth inhibition during this period. Our results showed that treatment with MSA increased the stability of GKLF mRNA in both cell lines (Fig. 2) . MSA does not change the activity of a 1 kb proximal GKLF promoter. In order to study the effect of MSA on GKLF promoter activity, a luciferase reporter gene construct containing about 1 kb fragment of the proximal promoter region of the GKLF gene (kindly provided by Dr. Vincent W. Yang at the Emory University) was transiently transfected into PC-3 and LNCaP cells. The luciferase reporter assay was carried out at 1 hr, 2 hr, 3 hr, 6 hr, or 16 hr after treatment with 10 μM MSA. As can be seen in Fig. 3 , MSA treatment did not result in any significant change in the activity of this 1 kb GKLF promoter. The data indicate that either MSA does not affect GKLF mRNA transcription initiation, or the cis element(s) mediating MSA effect is not present in this 1 kb promoter region of the GKLF gene.
Results for Task 2 (To determine the effect of GKLF overexpression on the growth of prostate cancer cells as well as selenium growth inhibition):
Overexpression of GKLF enhances MSA inhibition of DNA synthesis in PC-3 cells. In an attempt to investigate the biological consequence of GKLF induction by MSA, we transiently transfected PC-3 cells with a GKLF expression construct, pcDNA3.1/His B-GKLF (kindly 
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provided by Dr. Anil K. Rustgi at the University of Pennsylvania) and assessed the effect of GKLF overexpression on MSA growth inhibition. Cell proliferation was quantified with the combined use of the cell viability detection reagent WST-1 (Roche) and a BrdU ELISA system (Roche), which measures BrdU incorporation during DNA synthesis. The BrdU ELISA data were normalized by the WST-1 results to correct for the differences in cell number. As shown in Fig. 4 , after exposure to 5 µM MSA for 16 hr, DNA synthesis was suppressed by 37% in cells transfected with the mock vector. The suppression was significantly greater (50%, P < 0.05) in cells overexpressing GKLF. Overexpression of GKLF induces apoptosis and enhances the effect of MSA on apoptosis induction in PC-3 cells. We next assessed the effect of GKLF overexpression on MSA induction of apoptosis by using the Cell Death Detection ELISA PLUS kit (Roche), which quantitatively detects apoptotic nucleosomes. As shown in Fig. 5 , exogenous expression of GKLF in PC-3 cells led to a significant increase of apoptosis. In addition, the effect of MSA on apoptosis induction was greatly enhanced by GKLF overexpression (P < 0.01 compared with MSA-treated mock-transfectants). The results are expressed as increase of apoptosis compared with untreated mocktransfectants. *, P < 0.01, statistically different from untreated mock-transfectants. **, P < 0.01, statistically different from untreated GKLF-transfectants and MSAtreated mock-transfectants. GKLF knockdown weakens the growth suppressive activity of MSA in PC-3 cells. In order to further establish the role of GKLF induction in mediating MSA action, we adopted the small interference RNA (siRNA) technique to knock down the expression of GKLF. The predesigned Stealth™ Select RNAi for GKLF from Invitrogen was used in this study. The siRNA at a concentration of 40 nM was transiently transfected into PC-3 cells using the Lipofectamine 2000 reagent (Invitrogen). As shown in Fig. 6 , the GKLF siRNA transfection not only markedly repressed basal GKLF mRNA expression (~90%), but also prevented the induction of this gene by MSA.
The response of the GKLF knockdown cells to MSA-mediated DNA synthesis inhibition was subsequently examined. The BrdU ELISA assay was performed at 16 hr after 10 µM MSA treatment, and the data are presented in Fig. 7 . MSA treatment inhibited DNA synthesis by 73% in the scrambled siRNAtransfected cells, as opposed to 50% in the GKLF siRNA-transfected cells (P < 0.01). Thus, GKLF knockdown was able to significantly mitigate the growth suppressive activity of MSA.
% of scrambled control GKLF knockdown attenuates the apoptosis induction activity of MSA in PC-3 cells. MSA-induced apoptosis was also examined in the GKLF knockdown cells. Without MSA treatment, no difference was observed in apoptosis between transfection with scrambled siRNA or GKLF siRNA (data not shown). In cells treated with 10 µM MSA for 16 hr, MSA-mediated apoptosis induction was greatly attenuated by GKLF gene knockdown (P < 0.01). Together with the BrdU data, our results demonstrated an important role of GKLF induction in mediating the growth inhibitory and apoptosis inducing actions of MSA. To determine whether MSAmediated downregulation of AR was due to increased mRNA degradation or decreased transcription, we performed an mRNA stability assay. The protocol is the same as described above. Our results showed that treatment with 10 μM MSA actually increased the stability of AR mRNA (Fig. 9A ). We then studied the effect of MSA on AR transcription by nuclear run-on assay. Biotinlabeled nascent transcripts obtained by run-on transcription were isolated by using streptavidin particle beads, and quantitated by real-time RT-PCR. To differentiate the effect of MSA on transcription initiation and on transcription elongation, the real-time RT-PCR analysis was conducted with a primer-probe set corresponding to either the 5'-end or the 3'-end of the AR mRNA. For both sets of primer-probe, MSA treatment resulted in ~80% and 87% inhibition of AR transcription at 3 hr and 6 hr, respectively (Fig. 9B) . The data thus indicate that the decrease in AR mRNA level by MSA is accounted for by a vigorous block of AR transcription initiation.
Inhibition of AR promoter activity by MSA.
Gene transcription is generally controlled by promoter regions. In order to study the effect of MSA on AR promoter activity, we PCR amplified an 8 kb and a 1.7 kb fragment of the 5'-flanking region of the human AR gene from an AR-containing BAC clone. The 8 kb fragment (-6885 to +1115) contains ~6.9 kb of the 5'-flanking region upstream of the entire 5'-untranslated region (UTR), and the 1.7 kb fragment (-600 to +1115) contains 600 bp of the 5'-flanking region upstream of the entire 5'-UTR. These two promoter regions were then cloned into the pGL4.19[luc2CP/Neo] rapid response luciferase expression vector (Promega). The inclusion of the protein degradation sequences in this vector allows the reporter to be highly responsive and suitable for monitoring rapid response. The authenticity of the constructs, pGL4-8kb-ARpromoter and pGL4-1.7kb-AR-promoter, was confirmed by DNA sequencing. The two constructs were transiently transfected into LNCaP cells cultured in a defined medium (RPMI1640 plus 2% albumax) without androgen to avoid the confounding effect of AR auto-regulation. The treatment duration was 1 hr, at a time when there was no detectable decrease of AR protein. As shown in Fig. 10 , MSA induced a ~60% inhibition of the activity of both promoters. The data therefore indicate that the cis element(s) mediating MSA downregulation of AR is present in the 1.7 kb promoter region. We are in the process of further characterizing such cis-element(s). It is generally believed that unliganded AR localizes in the cytoplasm as a heteromeric complex with heat shock proteins (1, 2) . Upon binding to androgens, AR undergoes conformational change, dissociates from the heteromeric partners, forms a homodimer through the interaction of AR N-and C-terminal regions, and translocates into nucleus to initiate target gene regulation (1, 2) . In addition, the trans-activating activity of AR is modulated by other transcription factors and coregulators (3). Our previous data suggest that MSA may disrupt AR signaling through additional mechanism(s) beyond reducing the availability of the AR protein. We therefore assessed the effect of MSA on the ligand-binding activity of AR. 
C. KEY RESEARCH ACCOMPLISHMENTS:
Selenium upregulates GKLF mRNA level through decreasing GKLF mRNA degradation.
Overexpression of GKLF enhances selenium inhibition of DNA synthesis in the AR-null PC-3 cells.
Overexpression of GKLF induces apoptosis and enhances the effect of selenium on apoptosis induction in PC-3 cells.
GKLF knockdown weakens the DNA synthesis suppressive activity of selenium in PC-3 cells.
GKLF knockdown attenuates the apoptosis induction activity of selenium in PC-3 cells.
Selenium treatment significantly decreases the expression of androgen receptor (AR) and prostate specific antigen (PSA) in five human prostate cancer cell lines (LNCaP, LAPC-4, CWR22Rv1, LNCaP-C81 and LNCaP-LN3), irrespective of their AR genotype (wildtype vs. mutant) or sensitivity to androgen-stimulated growth.
Selenium inhibition of five AR-regulated genes implicated in prostate carcinogenesis (PSA, KLK2, ABCC4, DHCR24, and GUCY1A3) is significantly attenuated by AR overexpression.
Transfection of AR in LNCaP cells weakens significantly the inhibitory effect of selenium on cell growth and proliferation.
Selenium downregulates AR mRNA level through inhibiting AR transcription initiation.
The cis element(s) mediating selenium downregulation of AR is present in a 1.7 kb proximal promoter region (-600 to +1115).
Selenium treatment does not alter the ligand-binding capacity or affinity of AR.
Selenium treatment leads to a significant suppression of AR N-C dimerization.
D. REPORTABLE OUTCOMES:
Publications: 
E. CONCLUSIONS:
The results from the current study indicate an important role of GKLF induction in mediating the growth suppressive and apoptosis induction activities of selenium in the AR-null PC-3 cells. However, in cells expressing a functional AR, the disruption of AR signaling is most likely more important than the induction of GKLF signaling for selenium action. The vast majority of prostate cancers express a functional AR. Although GKLF has growth suppressive activity in the AR-null cells, such activity might be overshadowed by AR signaling in ARexpressing cells. Therefore, it would be imperative to continue our research effort on the study of selenium suppression of AR signaling.
Almost all patients with advanced prostate cancer respond initially to treatments that interfere with the AR signaling process. However, these treatments often fail after prolonged use and recurrence becomes a major clinical issue (5) . The development of hormone refractory prostate cancer is not associated with loss of AR (6, 7) . Instead, the accumulation of several molecular alterations frequently leads to a lower threshold requirement of androgens for the proliferation and survival of prostate cancer cells. Amplification and/or overexpression of AR can hyper-sensitize cells to sub-physiological levels of androgens (8) (9) (10) (11) . A recent report by Chen et al. (8) claimed that increased AR expression is both necessary and sufficient to convert prostate cancer growth from androgen-dependent to -independent, and that AR antagonists may display agonistic activity in cells with elevated AR expression. In addition, AR gene mutations could result in a promiscuous receptor with a broad ligand-binding and trans-activation spectrum (12) . A selenium intervention strategy aimed at diminishing the expression of AR could be helpful not only for reducing prostate cancer incidence, but also for preventing relapses after endocrine therapy. In addition, the fact that selenium suppresses AR signaling provides a sound rationale for using selenium in combination with an anti-androgen as a new modality for not only the prevention but also the treatment of prostate cancer. 
Introduction
Prostate cancer is the second most common cancer and the second leading cause of cancer death in men in the United States. Androgen plays an important role not only in maintaining the function of the prostate but also in promoting the development of prostate cancer (1) . Androgen binds to the androgen receptor, which subsequently translocates to the nucleus and interacts with specific androgen-responsive elements (ARE) on the promoters of target genes. The interaction leads to the activation or repression of genes involved in the proliferation and differentiation of the prostate cells (2). Prostatespecific antigen (PSA) and kallikrein 2 (KLK2) are two well-accepted targets of androgen receptor. PSA, also known as kallikrein 3, is an established serum marker for the diagnosis and prognosis of prostate cancer. Although KLK2 is not as widely used as PSA, it is increasingly recognized to provide added information to disease staging (3, 4). The randomized, placebo-controlled Nutritional Prevention of Cancer trial showed that selenium supplementation reduced the incidence of prostate cancer by 50% (5, 6) . This trial was designed initially to assess the effect of selenium on nonmelanoma skin cancer. Because men accounted for a sizable proportion of the cohort (974 of a total of 1,312), there was sufficient power to analyze the changes in prostate cancer risk. When the prostate cancer data were further stratified, there was evidence of a greater reduction in risk from selenium supplementation among men who had low baseline plasma PSA levels (6). Early-stage prostate cancer is mostly responsive to androgen stimulation. The inference that the protective effect of selenium might be more pronounced in earlystage prostate cancer, as reflected by low PSA secretion, lends credence to the idea that selenium might affect androgen signaling.
Recently, we reported that a selenium metabolite, in the form of methylseleninic acid (MSA), greatly down-regulates the expression of androgen receptor and PSA in the androgen-responsive LNCaP human prostate cancer cells (7, 8) . The suppression of androgen receptor signaling occurs well before any significant growth inhibition, which is accompanied by correlative changes in numerous cell cycle and apoptosis regulatory molecules (9 -13). Androgen receptor signaling involves multiple steps, the receptor itself is just one of many effectors that participate in the process. For example, heat shock proteins are known to modulate the stability of androgen receptor as well as its affinity to androgen (14, 15) . The transactivating activity of androgen receptor can be affected markedly by a large number of coactivators and corepressors (16) . Our microarray analysis suggests that MSA alters the expression of several heat shock proteins, coactivators, and corepressors of the superfamily of steroid hormone receptors (17) . In view of these confounding effects, the present study was designed to determine the role of androgen receptor down-regulation per se in MSA interference of androgen receptor signaling. Our approach was to use the ARE-luciferase reporter gene assay to find out the extent to which selenium suppression of androgen receptor transactivation could be reversed when the luciferase activity is normalized based on androgen receptor protein level. We also investigated whether androgen receptor transfection might attenuate selenium-mediated down-regulation of five androgen receptor targets: PSA, KLK2, ATP-binding cassette C4 (ABCC4, also known as MRP4), 24-dehydrocholesterol reductase (DHCR24, also known as seladin-1), and soluble guanylate cyclase 1 a 3 (GUCY1A3). These five androgen-inducible genes were selected based on the criteria that they are consistently overexpressed in prostate cancer compared with normal prostate tissue (18) . Finally, in an effort to evaluate the biological significance of the selenium-androgen receptor signaling axis, we investigated whether androgen receptor overexpression might block the growth inhibitory effect of selenium.
Materials and Methods
Selenium Reagent, Prostate Cancer Cell Lines, 3-(4,5-dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide Assay, and Bromodeoxyuridine-Labeling Analysis MSA was synthesized as previously described (19) . The LNCaP and CWR22Rv1 human prostate cancer cell lines were obtained from American Type Culture Collection (Manassas, VA). The LAPC-4 cell line was provided by Dr. Charles L. Sawyers at the University of California at Los Angeles Jonsson Comprehensive Cancer Center. The two androgen-unresponsive LNCaP sublines, LNCaP-LN3 and LNCaP-C81, were obtained from Dr. Curtis A. Pettaway (University of Texas M.D. Anderson Cancer Center) and Dr. Ming-Fong Lin (University of Nebraska Medical Center), respectively. The cells were cultured in RPMI 1640 supplemented with 10% fetal bovine serum, 100 unit/mL penicillin, 100 Ag/mL streptomycin, and 2 mmol/L glutamine. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for cell growth and the bromodeoxyuridine (BrdUrd) labeling for DNA synthesis were done as described in our previous publication (17) .
Transient Transfection of Androgen Receptor
The procedure was carried out using the Lipofect-AMINE Plus reagent (Invitrogen, Carlsbad, CA) per instruction of the manufacturer. At 24 hours before transfection, cells were plated in growth medium without antibiotics at a density to reach 90% to 95% confluency at transfection. The pSG5hAR androgen receptor expression vector (20) or the pSG5 mock plasmid (Stratagene, La Jolla, CA) was introduced into LNCaP cells with or without the cotransfection of the pEGFP-F membrane-GFP-encoding construct (BD Biosciences, San Jose, CA). The purpose of the green fluorescent protein (GFP) was to enable us to enrich for the subset of positively androgen receptor -transfected cells. During cotransfection, the two plasmids were added at 1:1 molar ratio. The amount of DNA transfected was 12 Ag per 10-cm culture dish. The DNA/liposome mixture was removed at 3 hours after transfection. For the MTT assay, the cells were trypsinized 16 hours later and plated in triplicate onto a 96-well plate. Cells were allowed to recover for an additional 24 hours before exposure to 10 Amol/L MSA. The MTT assay was conducted at 48 hours post-MSA treatment. For the BrdUrd-labeling analysis, the cells were subjected to MSA treatment at 24 hours posttransfection and labeled with BrdUrd after 24 hours of MSA treatment.
Reporter Gene Assay The ARE-luciferase reporter plasmid, containing three repeats of the ARE region ligated in tandem to the luciferase reporter (20) , was transiently transfected into cells at a concentration of 9 Ag per 10-cm culture dish. After incubating with the transfection mixture for 3 hours, the cells were trypsinized, resuspended in medium containing charcoal-stripped serum and 10 nmol/L dihydrotestosterone (Sigma, St. Louis, MO), and plated in triplicate onto 6-well plates. Cells were allowed to recover for an additional 24 hours before exposure to 10 Amol/L MSA. After 6 or 16 hours of MSA treatment, cells were lysed in reporter lysis buffer (Promega, Madison WI), and the luciferase activity was assayed using the Luciferase Assay System (Promega). Protein concentration in cell extracts was determined by the bicinchoninic acid protein assay kit (Pierce, Rockford, IL). Luciferase activities were normalized by the protein concentration of the sample. The transfection experiments were repeated thrice.
Western Blot Analysis Details of the procedure for Western blot analysis were described previously (17) . Immunoreactive bands were quantitated by volume densitometry and normalized to glyceraldehyde-3-phosphate dehydrogenase. The following monoclonal antibodies were used in this study (source): anti-glyceraldehyde-3-phosphate dehydrogenase (Chemicon, Temecula, CA), anti -androgen receptor (BD Biosciences), and anti-PSA (Lab Vision, Fremont, CA).
Real-time Reverse Transcription-PCR Real-time reverse transcription-PCR analysis was done as described previously (21) . The PCR primers and Taqman probes for h-actin, androgen receptor, PSA, KLK2, ABCC4, DHCR24, and GUCY1A3 were Assayson-Demand products from Applied Biosystems (Foster City, CA). The PCR conditions were as follows: an initial incubation at 50jC for 2 minutes, then a denaturation at 95jC for 10 minutes followed by 40 cycles of 95jC for 15 seconds and 60jC for 1 minute. The relative quantitation of gene expression was done using the comparative C T (DDC T ) method (22) .
Androgen Receptor mRNA Stability Assay Actinomycin D (5 Ag/mL) was added to the cultures to stop new RNA synthesis at the time of MSA treatment, and androgen receptor mRNA levels were measured by real-time reverse transcription-PCR at hourly intervals for the next 6 hours. The turnover of androgen receptor mRNA was determined by comparing mRNA levels over time in cells treated with or without MSA.
Statistical Analysis
The Student's two-tailed t test was used to determine significant differences between treatment and control values, and P < 0.05 was considered statistically significant. Figure 1 shows the effect of MSA on androgen receptor transcript and protein levels as well as androgen receptor mRNA stability in LNCaP cells. The decrease in androgen receptor transcript, as determined by real-time reverse transcription-PCR, occurred very quickly (Fig. 1A) . On the average, there was about a 50% reduction in the first three hours after treatment with 10 Amol/L MSA; by 6 hours, the magnitude of inhibition rose to 80%. At the protein level, there was no change in androgen receptor in the first two hours (Fig. 1B) . A modest decrease began to appear at 3 hours, and the inhibition became very pronounced at 6 hours (Fig. 1B) . The observation is consistent with the time-dependent sequence of reduced mRNA leading to decreased protein expression. To determine whether the down-regulation of androgen receptor mRNA was due to decreased transcription or increased mRNA degradation, we did an mRNA stability assay under the condition in which new RNA synthesis was blocked. Actinomycin D was added to the culture at the time of MSA treatment, and androgen receptor mRNA levels were followed in a 6-hour time course experiment. Because actinomycin D could be cytotoxic, we also monitored cell growth for up to 8 hours and did not observe cell death or significant growth inhibition during this period. Our results showed that treatment with MSA actually increased the stability of androgen receptor mRNA (Fig. 1C) . This observation rules out increased mRNA degradation as a contributing factor. Therefore, the decrease in androgen receptor mRNA level by MSA is likely to be accounted for by a vigorous block of androgen receptor transcription.
Results
MSA Depresses Androgen Receptor Transcription
We next examined the effect of MSA on the expression of androgen receptor and PSA in four additional human prostate cancer cell lines: LAPC-4, CWR22Rv1, LNCaP-C81, and LNCaP-LN3. The LAPC-4 cells are androgen responsive and express a wild-type androgen receptor (23) , as opposed to LNCaP cells that are also androgen responsive but express a mutant, although functional, androgen receptor. The other three cell lines are all androgen-unresponsive and express a mutant but functional androgen receptor (24 -27) . As shown in Fig. 2 (left) , MSA decreased androgen receptor and PSA transcript levels progressively as a function of time in all four cell lines examined. The reduction in androgen receptor and PSA proteins (right) paralleled the drop in the transcripts. In LAPC-4, CWR22Rv1, and LNCaP-C81 cells, a decrease in PSA transcript was already detectable as early as 3 hours, at a time when there was no apparent loss of the androgen receptor protein. The data suggest that MSA disrupts androgen receptor signaling through additional mechanism(s) beyond reducing the availability of the androgen receptor protein. 
MSA-Mediated Androgen Receptor Down-Regulation Leads to a Reduction of Androgen Receptor Transactivating Activity
The transactivation of androgen receptor is an indicator of androgen receptor signaling and can be quantified readily by a reporter gene assay. To investigate whether the reduced availability of androgen receptor by MSA is a major factor in modulating androgen receptor transcriptional activity, we transiently transfected LNCaP cells with the ARE-luciferase reporter plasmid and normalized the luciferase activity based on the level of the androgen receptor protein. This normalization step eliminates the level of androgen receptor expression as a determinant of androgen receptor transactivation. The luciferase reporter assay was carried out at 6 and 16 hours after treatment with 10 Amol/L MSA. At these two time points, androgen receptor protein level was inhibited by 60% and 77%, respectively (Fig. 3B, inset) . As can be seen in Fig. 3A , without normalizing for the difference in androgen receptor protein level between the MSA-treated and -untreated samples, the ARE-promoter activity was decreased by 65% or 75%, respectively, after 6 or 16 hours of MSA treatment. However, after normalization, the ARE-promoter activity was inhibited by a meager 15% at the 6-hour time point, and the inhibition disappeared completely at 16 hours (Fig. 3B) . These findings suggest that the reduced availability of the androgen receptor protein is the major factor in contributing to MSA disruption of androgen receptor signaling. 
Overexpression of Androgen Receptor Attenuates the Effect of MSA on the Down-Regulation of Androgen Receptor^Regulated Genes
To delineate the role of low androgen receptor abundance as a cause of reduced PSA expression by selenium, we transiently transfected LNCaP cells with a wild-type androgen receptor construct and determined the response of PSA to MSA. After 3 hours of MSA exposure, PSA transcript was depressed by about 75% in the mocktransfected cells but only by about 45% in the androgen receptor -transfected cells (Fig. 4A) . Based on our routine experience of a 40% transfection efficiency as determined by GFP cotransfection analysis (described below), we believe that the inhibitory effect of MSA on PSA mRNA might have been reversed completely in positive androgen receptor transfectants. Our conclusion was derived from the following theoretical calculation: 40% of (1 À x) + 60% of (1 À a) = 1 À b, where x = % inhibition in positive androgen receptor transfectants, a = 75% inhibition in mock transfectants, and b = 45% inhibition in the mixed population of androgen receptor -transfected cells. Solving for x in the above equation gave a value of 0% inhibition. In other words, there was no inhibition of PSA expression by MSA in the positive androgen receptor transfectants (i.e., complete reversal). The difference between the mock-and androgen receptor -transfected cells, although still apparent, was not as great at 4 and 6 hours compared with that at 3 hours. The fact that a robust androgen receptor presence was not sufficient to completely counteract the suppressive effect of MSA on the transcription of PSA at the later time points suggests that there could be a delay in the recruitment of additional mechanisms by which MSA might diminish androgen receptor signaling. We also studied the protein level of PSA by Western blotting. The Western analysis was done at 24 hours after MSA treatment. As shown in Fig. 4B , PSA protein was depressed by about 70% in the mock-transfected cells but only by about 40% in the androgen receptor -transfected cells. The protein levels of androgen receptor in the mock-and androgen receptor -transfected cells are also shown in Fig. 4B for confirmation purposes.
Using a bioinformatic data mining approach, we recently identified five additional androgen-inducible genes that are expressed at a higher level in prostate cancer compared with normal prostate tissue; furthermore, their expression is repressed by MSA (18) . These genes are KLK2, ABCC4 (also known as MRP4), DHCR24 (also known as seladin-1), GUCY1A3, and long-chain fatty acid CoA ligase 3 (FACL3). MSA down-regulation of their expression only occurs in LNCaP cells but not in the androgen-unresponsive PC-3 cells that express an extremely low level of androgen receptor (18) . To verify that the decreased expression of these genes is a direct consequence of MSA suppression of androgen receptor signaling, we applied the same androgen receptor overexpression protocol as described above and used real-time reverse transcription-PCR to quantitate their transcript levels. The FACL3 gene was not included in this study as no Assays-on-Demand primers and probes are available for this gene. The results are shown in Fig. 5 . Androgen receptor transfection significantly muted the inhibition of gene expression by MSA. In general, the difference in % inhibition between the mock and androgen receptor transfectants was greatest at 3 hours and narrowed gradually with time. The overall pattern was very similar for KLK2, ABCC4, DHCR24, and GUCY1A3. The data thus show a key role of androgen receptor down-regulation in mediating the inhibitory effects of MSA on the expression of androgen receptor -regulated genes.
Overexpression of Androgen Receptor Interferes with MSA-Mediated Growth Inhibition
In an effort to evaluate the biological significance of MSA suppression of androgen receptor signaling, we transiently transfected LNCaP cells with a wild-type androgen receptor and assessed the response of the androgen receptor -overexpressing cells to MSA-induced growth inhibition. The MTT assay was conducted at 48 hours post-MSA, and the data are presented in Fig. 6A . In the absence of MSA, cell growth was not altered by the transfection of androgen receptor (data not shown), indicating that the endogenous level of androgen receptor is not a limiting factor for the growth of these cells. MSA treatment inhibited growth by 40% in the mock transfectants, as opposed to 27% in the androgen receptor transfectants. The difference is statistically significant (P = 0.003). Thus, androgen receptor overexpression was able to weaken the growth suppressive activity of MSA. One reason that the difference was seemingly compressed was due to the fact that only a fraction of cells was successfully transfected, and in this study, cell growth was assessed using the whole cell population. To address the last problem, we cotransfected cells with the androgen receptor expression vector and a membrane-GFP-encoding construct. The cells were then subjected to BrdUrd labeling, and the data were analyzed by gating just the GFP-positive cells. As shown in Fig. 6B , after selecting for the subset of GFP-positive cells, we found that MSA inhibited DNA synthesis by a very modest 16% in the androgen receptor transfectants, as opposed to 72% in the mock transfectants. Because the GFP and androgen receptor cDNAs are not located in the same plasmid construct, it is possible that not all the cells positive for GFP are also positive for the transfected androgen receptor. Thus, our selection process only led to an enrichment, rather than an exclusive selection, of double-positive cells. Therefore, the difference between the mock transfectants and the androgen receptor transfectants might have been even more pronounced if all the cells used in the experiment were successfully transfected with androgen receptor. Figure 6B also shows that when we did the BrdUrd labeling experiment with the nonenriched androgen receptor -transfected cells, the inhibition by MSA was about 45%, a value half-way between that achieved by the mock transfectants and the enriched androgen receptor transfectants.
Discussion
Our previous report showed that selenium significantly decreases the expression and the transactivating activity of androgen receptor in LNCaP cells (21) . The present study extended the above observations by showing the universality of this phenomenon and a key role of androgen receptor down-regulation in mediating the inhibitory effects of selenium on prostate cancer cell growth and the expression of cancer-specific biomarkers. First, selenium decreases the expression of androgen receptor and PSA in five human prostate cancer cell lines, irrespective of their androgen receptor genotype (wild type versus mutant) or sensitivity to androgen-stimulated growth. Second, a reporter gene assay with the ARE-luciferase construct indicated that depletion of the androgen receptor protein is a major factor for selenium depression of androgen receptor transactivating activity. Third, overexpression of androgen receptor greatly weakens the inhibitory effects of selenium on prostate cancer cell proliferation as well as the expression of five androgen receptor -regulated genes implicated in prostate carcinogenesis: PSA, KLK2, ABCC4, DHCR24, and GUCY1A3. These findings, however, do not necessarily exclude additional mechanisms by which selenium diminishes androgen receptor signaling (e.g., via modulation of ligand binding, androgen receptor dimerization, nuclear translocation, and the interaction of androgen receptor with its coregulators). In fact, our previous report provided some evidence that selenium is able to inhibit the binding of androgen receptor to the ARE in the absence of a drop in the androgen receptor level (21) .
A selenium intervention strategy aimed at diminishing the expression of androgen receptor could be helpful not only for reducing prostate cancer incidence but also for preventing relapses after endocrine therapy. Almost all patients with advanced prostate cancer respond initially to treatments that interfere with the androgen receptorsignaling process. However, these treatments often fail after prolonged use and recurrence becomes a major clinical issue (28) . The development of hormone refractory prostate cancer is not associated with loss of androgen receptor (29, 30) . Instead, the appearance of several molecular alterations frequently leads to a lower threshold requirement of androgens for the proliferation and survival of prostate cancer cells. Androgen receptor gene mutations could result in a promiscuous receptor with a broad ligandbinding and transactivation spectrum (31) . Amplification and/or overexpression of androgen receptor may hypersensitize cells to subphysiologic levels of androgens (32 -35) . A recent report by Chen et al. (35) claimed that increased androgen receptor expression is both necessary and sufficient to convert prostate cancer growth from androgen-dependent to -independent and that androgen receptor antagonists may display agonistic activity in cells with elevated androgen receptor expression. On the other hand, several studies showed that knocking down the expression of androgen receptor inhibits the growth of prostate cancer cells, both in vitro and in vivo, and induces apoptosis (36 -39) . Because selenium blocks the transcription of androgen receptor (see Fig. 1 ), this treatment modality may prove to be effective in prostate cancer intervention.
The down-regulation of androgen receptor targets by selenium has important clinical implication. We have studied PSA, KLK2, ABCC4, DHCR24, and GUCY1A3. All these genes are expressed at a higher level in prostate cancer compared with normal prostate tissue (18) . PSA and KLK2 are prostate-specific differentiation markers. They belong to the serine protease family and are both secretory proteins. PSA is the most useful serum marker for the diagnosis and prognosis of prostate cancer. The combined use of PSA and KLK2 has been shown to improve the specificity of biochemical detection of prostate cancer (40 -44) and the accuracy in predicting tumor grade and 
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stage (3, 4) . ABCC4 (also known as MRP4) is a member of the multidrug resistance-associated protein family of transporters. Overexpression of ABCC4 in neuroblastoma is associated with poor prognosis and resistance to the topoisomerase I poison irinotecan and its active metabolite SN-38 (45) . Thus, the down-regulation of MRP4 by selenium might represent a potential mechanism by which selenium enhances the therapeutic efficacy of a number of anticancer drugs, including irinotecan (46) . DHCR24 (also known as seladin-1) is an antiapoptotic protein, it inhibits the activity of caspase 3 (47) . The overexpression of this gene has also been reported in adrenocortical adenoma cells compared with adjacent nontumor cells (48) . GUCY1A3 catalyzes the conversion of GTP to the second messenger cyclic guanosine 3V,5V-monophosphate, which regulates the activity of protein kinases, phosphodiesterases, and ion channels (49) . Future selenium intervention trial may consider monitoring androgen receptor, PSA, KLK2, ABCC4, DHCR24, and GUCY1A3 in biopsied prostate samples, to obtain a more comprehensive picture of an individual's responsiveness to selenium. Recent data also showed that cellular PSA is more sensitive than secretory PSA to selenium intervention (50) . This is one more reason why it is preferable to do the analysis in biopsied prostate tissue.
